PT - JOURNAL ARTICLE AU - Yannick Turdo AU - Tinh-Hai Collet TI - Statin intolerance – Prevalence and practical management in a specialized lipid clinic AID - 10.1101/2022.05.05.22274716 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.05.22274716 4099 - http://medrxiv.org/content/early/2022/05/05/2022.05.05.22274716.short 4100 - http://medrxiv.org/content/early/2022/05/05/2022.05.05.22274716.full AB - Aims Statins are recommended as first-line treatment to prevent cardiovascular disease, but high rates of adverse events and subsequent discontinuation can prevent effective treatment in some patients. We aimed to describe the intensity, nature and frequency of adverse effects caused by statins and other lipid-lowering drugs, and to assess their association with clinical predictors and treatment strategies.Methods This is a retrospective study of 121 consecutive unselected patients followed at a specialized lipid referral clinic in Lausanne University Hospital, Switzerland, in 2018 whose clinical data spanned 2016 until 2019.Results Adverse effects were reported by 58% of patients, causing musculoskeletal (72%), neurologic (40%), gastrointestinal (25%) and other (25%) symptoms. Gastrointestinal symptoms affected 35% of women, but only 12% of men (p=0.06). Statins caused more adverse effects than other drugs, with atorvastatin (63%) and simvastatin (64%) achieving the lowest rates, pravastatin (87%) and fluvastatin (100%) the highest. Fenofibrate was associated with significantly less frequent adverse effects than statins (22% vs. 57%, p=0.006). Adaptation and termination of the treatment led to 86% and 88% lower intensity of symptoms, respectively.Conclusion While the predominance of musculoskeletal symptoms caused by lipid-lowering drugs is known, symptoms affecting other organ systems should not be ignored. Statins were the lipid-lowering drug class with the highest rates of adverse effects. To maintain compliance and cardiovascular prevention, treatment strategies such as a change of dosage, frequency of administration, daily timing, or switching active substance can contribute to better tolerance of statin treatment. Further investigation is needed to establish specific treatment strategies for individual patient profiles.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland. T.H.C.'s research is supported by grants from the Swiss National Science Foundation (PZ00P3-167826), the Leenaards Foundation (2019), the Vontobel Foundation, the SwissLife Jubiläumsstiftung Foundation, the Medical Board of the Geneva University Hospitals, the Nutrition 2000plus Foundation, the Swiss Society of Endocrinology and Diabetes, and the Swiss Multiple Sclerosis Society. The funding bodies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The local ethics committee (Commission cantonale d'éthique de la recherche sur l'être humain [CER-VD], Lausanne, Switzerland) approved the study protocol and waived the requirement for individual informed consent of this anonymous retrospective review of electronic medical records.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this article cannot be shared publicly because of patient's confidentiality issue.